Fragile X at a turning point: Breaking through the clinical bottleneck

<p>In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder &amp; CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.</p><p></p><p><b>Host</b></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpace</p><p></p><p><b>Guests</b></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/hilary-rosselot/" target="_blank">Hilary Rosselot</a>, Executive Director, National Fragile X Foundation</p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/fabregajordi/" target="_blank">Jordi Fàbrega</a>, Co-Founder &amp; CEO, CONNECTA Therapeutics</p><p></p><p><i>Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.</i></p>